These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 20180535)
1. Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs. DeGraw AJ; Keiser MJ; Ochocki JD; Shoichet BK; Distefano MD J Med Chem; 2010 Mar; 53(6):2464-71. PubMed ID: 20180535 [TBL] [Abstract][Full Text] [Related]
2. BRET-based β-arrestin2 recruitment to the histamine H1 receptor for investigating antihistamine binding kinetics. Bosma R; Moritani R; Leurs R; Vischer HF Pharmacol Res; 2016 Sep; 111():679-687. PubMed ID: 27468652 [TBL] [Abstract][Full Text] [Related]
3. General unknown screening procedure for the characterization of human drug metabolites: Application to loratadine phase I metabolism. Picard N; Dridi D; Sauvage FL; Boughattas NA; Marquet P J Sep Sci; 2009 Jul; 32(13):2209-17. PubMed ID: 19569100 [TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras. Novotny CJ; Hamilton GL; McCormick F; Shokat KM ACS Chem Biol; 2017 Jul; 12(7):1956-1962. PubMed ID: 28530791 [TBL] [Abstract][Full Text] [Related]
5. 3D-QSAR with the aid of pharmacophore search and docking-based alignments for farnesyltransferase inhibitors. Vaidya M; Weigt M; Wiese M Eur J Med Chem; 2009 Oct; 44(10):4070-82. PubMed ID: 19515462 [TBL] [Abstract][Full Text] [Related]
6. Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis. Hou Y; Ge S; Li X; Wang C; He H; He L Chem Biol Interact; 2021 Apr; 338():109420. PubMed ID: 33609497 [TBL] [Abstract][Full Text] [Related]
7. Farnesyltransferase inhibitor as anticancer agent. Agrawal AG; Somani RR Mini Rev Med Chem; 2009 Jun; 9(6):638-52. PubMed ID: 19519490 [TBL] [Abstract][Full Text] [Related]
8. Inhibitors of protein farnesyltransferase as novel anticancer agents. Ohkanda J; Knowles DB; Blaskovich MA; Sebti SM; Hamilton AD Curr Top Med Chem; 2002 Mar; 2(3):303-23. PubMed ID: 11944822 [TBL] [Abstract][Full Text] [Related]
9. Structure-based design of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase. Ohkanda J; Strickland CL; Blaskovich MA; Carrico D; Lockman JW; Vogt A; Bucher CJ; Sun J; Qian Y; Knowles D; Pusateri EE; Sebti SM; Hamilton AD Org Biomol Chem; 2006 Feb; 4(3):482-92. PubMed ID: 16446806 [TBL] [Abstract][Full Text] [Related]
10. Caged protein prenyltransferase substrates: tools for understanding protein prenylation. DeGraw AJ; Hast MA; Xu J; Mullen D; Beese LS; Barany G; Distefano MD Chem Biol Drug Des; 2008 Sep; 72(3):171-81. PubMed ID: 18844669 [TBL] [Abstract][Full Text] [Related]
11. A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group. Tanaka A; Radwan MO; Hamasaki A; Ejima A; Obata E; Koga R; Tateishi H; Okamoto Y; Fujita M; Nakao M; Umezawa K; Tamanoi F; Otsuka M Bioorg Med Chem Lett; 2017 Aug; 27(16):3862-3866. PubMed ID: 28666734 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I. Qiao Y; Gao J; Qiu Y; Wu L; Guo F; Lo KK; Li D Eur J Med Chem; 2011 Jun; 46(6):2264-73. PubMed ID: 21440964 [TBL] [Abstract][Full Text] [Related]
14. Three-dimensional quantitative structure-farnesyltransferase inhibition analysis for some diaminobenzophenones. Xie A; Clark SR; Prasanna S; Doerksen RJ J Enzyme Inhib Med Chem; 2009 Dec; 24(6):1220-8. PubMed ID: 19912055 [TBL] [Abstract][Full Text] [Related]
15. New indolizine-chalcones as potent inhibitors of human farnesyltransferase: Design, synthesis and biological evaluation. Moise IM; Ghinet A; Belei D; Dubois J; Farce A; Bîcu E Bioorg Med Chem Lett; 2016 Aug; 26(15):3730-4. PubMed ID: 27282741 [TBL] [Abstract][Full Text] [Related]
16. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells. James G; Goldstein JL; Brown MS Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4454-8. PubMed ID: 8633088 [TBL] [Abstract][Full Text] [Related]